dry eye disease ded treatment is an area of increasing complexity with the emergence of several new treatment agents in recent yearsevaluation of the efficacy of these agents is limited by heterogeneity in outcomes definition and the small number of comparative studieswe provide a systematic review of clinical trials cts related to ded treatment and a critical appraisal of ct public databasesct reports obtained from eight databases were reviewed as well as public freeaccess electronic databases for ct registrationdata evaluation was based on endpoints such as symptoms schirmer test ocular surface staining scores recruitment of patients type and efficacy of the drug and the design and site of performance of the studyfortynine cts were evaluated involving 5189 patients receiving ded treatmentheterogeneity in study design prevented metaanalysis from yielding meaningful results and a descriptive analysis of these studies was conductedthe most frequent categories of drugs for ded in these studies were artificial tears followed by antiinflammatory drugs and secretagoguesalthough 116 studies have been completed according to the registration database for clinical trials only 17 of them 155 were publishedout of 185 registered cts related to ded 72 were performed in the usathe pharmaceutical industry sponsored 78 of themthe identification of effective ded treatment strategies is hindered by the lack of an accepted set of definitive criteria for evaluating disease severitycopyright  2013 elsevier inc all rights reserved